FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056765366> ?p ?o ?g. }

• W2056765366 endingPage "174" @default.
• W2056765366 startingPage "170" @default.
• W2056765366 abstract "PURPOSE The purpose of this study was to evaluate the clinical outcomes and compare complication rates for patients with prostate cancer treated with iodine 125 (125(125I) and palladium 103 (103Pd) prostate brachytherapy at a single institution. PATIENTS AND METHODS Between 1992 and 2002, 272 patients with prostate cancer were treated with ultrasound-guided transperineal implantation incorporating 125I (107 patients) or 103Pd (165 patients). Three months of hormonal therapy was incorporated into the treatment program in 33% of the patients in both groups. Nineteen percent of those treated with 125I were treated with a combination of implantation plus external-beam radiation therapy. Only 6% of the group receiving 103Pd implants were treated with such a combination. For those treated with 125I implantation alone, the minimum tumor dose was 145 Gy. The minimum tumor dose for those treated with 103Pd alone was 125 Gy. Those treated with a combination of external-beam radiation therapy and 125I received 45 Gy via 1.8-Gy fractions followed by implantation with a minimum tumor dose of 110 Gy. For those treated with externalbeam radiation therapy and 103Pd, the doses were 45 Gy via 1.8-Gy fractions followed by implantation with minimum tumor dose of 98 Gy. Outcomes were evaluated based on radionuclide used, T stage, Gleason score, prostate-specific antigen, and prognostic group. Complications were also evaluated for each radionuclide. The mean follow-up for the 125I group was 55 months, and the range was 12–108 months. The mean follow-up for the 103Pd group was 44 months, and the range was 12–72 months. RESULTS The 5-year biochemical disease-free survival rates for those in the favorable group (clinical stage T1c or T2, prostate-specific antigen level <10, Gleason score < 7) were 92% for the 125I group and 92% for the patients treated with 103Pd. The 5-year diseasefree survival rates for those in the intermediate and poor prognostic groups, which were combined, was 72% and 74%, respectively, for 125I and 103Pd. There was no statistically significant difference for either modality for any treatment group tested. In those treated with implantation alone, patients treated with 125I had higher complication rates than those treated with 103Pd (15% vs 4%). 125I-treated patients had a grade 2 complication rate of 8% and a grade 3–4 complication rate of 7%, compared with 3% and 1%, respectively, for the 103Pd-treated patients. CONCLUSION Despite the different management recommendations that evolved during the study period, the clinical outcome for patients treated with either radionuclide were similar with respect to biochemical disease-free survival. Although specific dosimetric comparisons are not valid given differences in imaging over the study course, the complication rate appears to be somewhat higher for 125I, which is consistent with a radiobiologic model." @default.
• W2056765366 created "2016-06-24" @default.
• W2056765366 creator A5037482302 @default.
• W2056765366 creator A5050318800 @default.
• W2056765366 creator A5052083936 @default.
• W2056765366 creator A5087631945 @default.
• W2056765366 creator A5089288351 @default.
• W2056765366 date "2004-05-01" @default.
• W2056765366 modified "2023-09-26" @default.
• W2056765366 title "Iodine 125 Versus Palladium 103 Implants for Prostate Cancer" @default.
• W2056765366 cites W1519205380 @default.
• W2056765366 cites W1984744014 @default.
• W2056765366 cites W2022266950 @default.
• W2056765366 cites W2052794398 @default.
• W2056765366 cites W2067980486 @default.
• W2056765366 cites W2068476226 @default.
• W2056765366 cites W2073673852 @default.
• W2056765366 cites W2081501463 @default.
• W2056765366 cites W2106147539 @default.
• W2056765366 cites W2316095838 @default.
• W2056765366 doi "https://doi.org/10.1097/00130404-200405000-00006" @default.
• W2056765366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15285926" @default.
• W2056765366 hasPublicationYear "2004" @default.
• W2056765366 type Work @default.
• W2056765366 sameAs 2056765366 @default.
• W2056765366 citedByCount "39" @default.
• W2056765366 countsByYear W20567653662012 @default.
• W2056765366 countsByYear W20567653662013 @default.
• W2056765366 countsByYear W20567653662015 @default.
• W2056765366 countsByYear W20567653662016 @default.
• W2056765366 countsByYear W20567653662017 @default.
• W2056765366 countsByYear W20567653662018 @default.
• W2056765366 countsByYear W20567653662019 @default.
• W2056765366 countsByYear W20567653662020 @default.
• W2056765366 countsByYear W20567653662022 @default.
• W2056765366 crossrefType "journal-article" @default.
• W2056765366 hasAuthorship W2056765366A5037482302 @default.
• W2056765366 hasAuthorship W2056765366A5050318800 @default.
• W2056765366 hasAuthorship W2056765366A5052083936 @default.
• W2056765366 hasAuthorship W2056765366A5087631945 @default.
• W2056765366 hasAuthorship W2056765366A5089288351 @default.
• W2056765366 hasConcept C121608353 @default.
• W2056765366 hasConcept C126322002 @default.
• W2056765366 hasConcept C126894567 @default.
• W2056765366 hasConcept C141071460 @default.
• W2056765366 hasConcept C201645570 @default.
• W2056765366 hasConcept C2775908122 @default.
• W2056765366 hasConcept C2776235491 @default.
• W2056765366 hasConcept C2777416452 @default.
• W2056765366 hasConcept C2778311097 @default.
• W2056765366 hasConcept C2780192828 @default.
• W2056765366 hasConcept C2989005 @default.
• W2056765366 hasConcept C509974204 @default.
• W2056765366 hasConcept C71924100 @default.
• W2056765366 hasConceptScore W2056765366C121608353 @default.
• W2056765366 hasConceptScore W2056765366C126322002 @default.
• W2056765366 hasConceptScore W2056765366C126894567 @default.
• W2056765366 hasConceptScore W2056765366C141071460 @default.
• W2056765366 hasConceptScore W2056765366C201645570 @default.
• W2056765366 hasConceptScore W2056765366C2775908122 @default.
• W2056765366 hasConceptScore W2056765366C2776235491 @default.
• W2056765366 hasConceptScore W2056765366C2777416452 @default.
• W2056765366 hasConceptScore W2056765366C2778311097 @default.
• W2056765366 hasConceptScore W2056765366C2780192828 @default.
• W2056765366 hasConceptScore W2056765366C2989005 @default.
• W2056765366 hasConceptScore W2056765366C509974204 @default.
• W2056765366 hasConceptScore W2056765366C71924100 @default.
• W2056765366 hasIssue "3" @default.
• W2056765366 hasLocation W20567653661 @default.
• W2056765366 hasLocation W20567653662 @default.
• W2056765366 hasOpenAccess W2056765366 @default.
• W2056765366 hasPrimaryLocation W20567653661 @default.
• W2056765366 hasRelatedWork W11918868 @default.
• W2056765366 hasRelatedWork W1523662141 @default.
• W2056765366 hasRelatedWork W2023984355 @default.
• W2056765366 hasRelatedWork W2127440557 @default.
• W2056765366 hasRelatedWork W3107045007 @default.
• W2056765366 hasRelatedWork W3110899715 @default.
• W2056765366 hasRelatedWork W4206581437 @default.
• W2056765366 hasRelatedWork W4285491790 @default.
• W2056765366 hasRelatedWork W4315647262 @default.
• W2056765366 hasRelatedWork W2342107002 @default.
• W2056765366 hasVolume "10" @default.
• W2056765366 isParatext "false" @default.
• W2056765366 isRetracted "false" @default.
• W2056765366 magId "2056765366" @default.
• W2056765366 workType "article" @default.